Everyday Health on MSN
C3G/IC-MPGN progression: Can new C3 inhibitors stop the path to dialysis?
For years, patients with C3G and IC-MPGN had few options to stop the progression toward kidney failure. Now a new class of ...
CRESTWOOD, Ky. and WALTHAM, Mass., July 18, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ...
In this analysis of patients with myeloperoxidase-ANCA-positive AAV, all urinary complement C3 fragment levels were elevated significantly compared with healthy controls (P .01 for all). Specific ...
Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
It was called ‘complement’ because it aided the antibacterial activity of antibodies. However, it is now known that the complement system can be activated early in an infection without the presence of ...
FDA approval of Novartis’s Fabhalta makes the drug the first approved oral therapy for rare blood disorder paroxysmal nocturnal hemoglobinuria. With clinical data showing superiority versus two ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results